Novo Nordisk Signs MOU with TEDA Biopharmaceutical Industry-Education Consortium

On April 19, Novo Nordisk and TEDA Biopharmaceutical Industry-Education Consortium jointly signed a memorandum of understanding on cooperation. Both parties will step up close collaboration between universities and enterprises and further develop distinctive apprenticeship programs. The joined effort will promote the integration of the education, industry, talent, and innovation chains, and explore the establishment of a two-way flow mechanism for vocational personnel and enterprise technical experts.

Since its establishment in 2023, TEDA Biopharmaceutical Industry-Education Consortium has actively promoted industrial technology education empowerment and innovation in various fields such as joint construction of universities and enterprises, talent cultivation, internships and practical training, technology supply and demand, and commercialization of sci-tech achievements.

Novo Nordisk is a global leading biopharmaceutical company headquartered in Denmark. Novo Nordisk (China) Pharmaceuticals Co., Ltd. was registered and established in TEDA in 1994. Over the past 30 years, it has continued to increase investment and expand production scale in TEDA. In 2018, it was designated as a Regional Headquarters of a Multinational Corporation by the Tianjin Municipal Commission of Commerce (now the Tianjin Commerce Bureau). The Tianjin factory is one of Novo Nordisk’s strategic global production bases and it supplies insulin durable injection devices and insulin products to the Chinese and global markets.